Spectrum Antimicrobials, Inc. — SEC Form D Filing
Spectrum Antimicrobials, Inc. filed an SEC Form D on April 1, 2026, reporting $26.39M raised in Pharmaceuticals.
Form D filing details
- Filing
- SEC Form D
- Filing date
- April 1, 2026
- Amount reported
- $26.39M
- Round stage
- Seed
- Industry
- Pharmaceuticals
- Website
- https://spectrumantimicrobials.com/
What the company does
Securities: Equity. Exemption: Rule 506(c). Incorporated: NEVADA
Problem
Spectrum Antimicrobials addresses the critical issue of infections in healthcare settings, including surgical sites and wound care.
Solution
The company develops proprietary antiviral and antimicrobial products that prevent infections and promote healing without encouraging drug resistance.
Why now
The increasing prevalence of antibiotic-resistant infections and a heightened awareness of infection control in healthcare necessitate innovative solutions.
Verdict
Investors said yes because Spectrum Antimicrobials presented a timely solution to the rising threat of antibiotic resistance, not because they had a clearly defined budget owner or replacement cost. The implicit bet was on a healthcare paradigm shift toward innovative infection control, but the limited upside lies in the crowded space of antimicrobial solutions where differentiation is crucial yet fragile.
Source: SEC EDGAR Form D filing